non small cell lung cancer
Conditions
Interventions
day 1: CBDCA 4AUC GEM 1000mg/m2 day 8: GEM 1000mg/m2
Sponsors
Kumamoto University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histologically or cytologically confirmed NSCLC who were 70 years or older at diagnosis, had measurable disease on thoracic computed tomography (CT) scans, and had not previously received chemotherapy were eligible for enrollment in the study. An additional requirement was that the disease was inoperable as a result of substantial comorbidity, impairment of respiratory function, or anatomic contraindication. Patients who relapsed after complete tumor resection or in whom resection was incomplete were also eligible. Further entry criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as well as adequate bone marrow (leukocyte count, 4000 to 12,000/µL; hemoglobin concentration, >9.0 g/dL; platelet count, >100,000/µL), renal (serum creatinine concentration, 70 torr) function.
Exclusion criteria
Exclusion criteria: Individuals with active infection, severe heart disease, active concomitant malignancy, or pleural or pericardial effusion requiring drainage were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Countries
Japan
Contacts
Public ContactJi-ichiro Sasaki
Kumamoto University School of Medicine Department of Respiratory Medicine
Outcome results
None listed